Medical Management of Brain Metastases and Leptomeningeal Disease in Patients with Breast Carcinoma

References

• Cheng X , HungMC. Breast cancer brain metastases. Cancer Metastasis Rev.26(3–4), 635–643 (2007).
   PubMed Web of Science ®Google Scholar
• Lin NU , BellonJR, WinerEP. CNS metastases in breast cancer. J. Clin. Oncol.22(17), 3608–3617 (2004).
   PubMed Web of Science ®Google Scholar
• Barnholtz-Sloan JS , SloanAE, DavisFG, VigneauFD, LaiP, SawayaRE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J. Clin. Oncol.22(14), 2865–2872 (2004).
   PubMed Web of Science ®Google Scholar
• Tsukada Y , FouadA, PickrenJW, LaneWW. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer52(12), 2349–2354 (1983).
   PubMed Web of Science ®Google Scholar
• Pestalozzi BC , ZahriehD, PriceKNet al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann. Oncol.17(6), 935–944 (2006).
   PubMed Web of Science ®Google Scholar
• Nam BH , KimSY, HanHSet al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res.10(1), R20 (2008).
   PubMed Web of Science ®Google Scholar
• Sperduto PW , KasedN, RobergeDet al. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. J. Neurooncol.112(3), 467–472 (2013).
   PubMed Web of Science ®Google Scholar
• Aversa C , RossiV, GeunaEet al. Metastatic breast cancer subtypes and central nervous system metastases. Breast23(5), 623–628 (2014).
   PubMed Web of Science ®Google Scholar
• Gaspar L , ScottC, RotmanMet al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int. J. Radiation Oncol. Biol. Phys.37(4), 745–751 (1997).
   PubMed Web of Science ®Google Scholar
• Sperduto PW , BerkeyB, GasparLE, MehtaM, CurranW. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int. J. Radiation Oncol. Biol. Phys.70(2), 510–514 (2008).
   PubMed Web of Science ®Google Scholar
• Subbiah IM , LeiX, WeinbergJSet al. Validation and development of a modified breast graded prognostic assessment as a tool for survival in patients with breast cancer and brain metastases. J. Clin. Oncol.33(20), 2239–2245 (2015).
   PubMed Web of Science ®Google Scholar
• Eichler AF , LoefflerJS. Multidisciplinary management of brain metastases. Oncologist12(7), 884–898 (2007).
   PubMed Web of Science ®Google Scholar
• Peacock KH , LesserGJ. Current therapeutic approaches in patients with brain metastases. Curr. Treat. Options Oncol.7(6), 479–489 (2006).
   PubMedGoogle Scholar
• Arslan C , DizdarO, AltundagK. Systemic treatment in breast-cancer patients with brain metastasis. Expert Opin. Pharmacother.11(7), 1089–1100 (2010).
   PubMed Web of Science ®Google Scholar
• Azad TD , PanJ, ConnollyID, RemingtonA, WilsonCM, GrantGA. Therapeutic strategies to improve drug delivery across the blood–brain barrier. Neurosurg. Focus38(3), E9 (2015).
   PubMed Web of Science ®Google Scholar
• Patel RR , MehtaMP. Targeted therapy for brain metastases: improving the therapeutic ratio. Clin. Cancer Res.13(6), 1675–1683 (2007).
   PubMed Web of Science ®Google Scholar
• Qin DX , ZhengR, TangJ, LiJX, HuYH. Influence of radiation on the blood–brain barrier and optimum time of chemotherapy. Int. J. Radiation Oncol. Biol. Phys.19(6), 1507–1510 (1990).
   PubMed Web of Science ®Google Scholar
• Scott BJ , KesariS. Leptomeningeal metastases in breast cancer. Am J. Cancer Res.3(2), 117–126 (2013).
   PubMed Web of Science ®Google Scholar
• de Azevedo CR , CruzMR, ChinenLTet al. Meningeal carcinomatosis in breast cancer: prognostic factors and outcome. J. Neurooncol.104(2), 565–572 (2011).
   PubMed Web of Science ®Google Scholar
• Lassman AB , AbreyLE, ShahGDet al. Systemic high-dose intravenous methotrexate for central nervous system metastases. J. Neurooncol.78(3), 255–260 (2006).
   PubMed Web of Science ®Google Scholar
• Kumthekar P , GrimmSA, AvramMJet al. Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases. J. Neurooncol.112(2), 247–255 (2013).
   PubMed Web of Science ®Google Scholar
• Franciosi V , CocconiG, MichiaraMet al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer85(7), 1599–1605 (1999).
   PubMed Web of Science ®Google Scholar
• Gruschow K , KlautkeG, FietkauR. Phase I/II clinical trial of concurrent radiochemotherapy in combination with topotecan for the treatment of brain metastases. Eur. J. Cancer38(3), 367–374 (2002).
   PubMed Web of Science ®Google Scholar
• Christodoulou C , BafaloukosD, KosmidisPet al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann. Oncol.12(2), 249–254 (2001).
   PubMed Web of Science ®Google Scholar
• Addeo R , De RosaC, FaiolaVet al. Phase II trial of temozolomide using protracted low-dose and whole-brain radiotherapy for non-small cell lung cancer and breast cancer patients with brain metastases. Cancer113(9), 2524–2531 (2008).
   PubMed Web of Science ®Google Scholar
• Rivera E , MeyersC, GrovesMet al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer107(6), 1348–1354 (2006).
   PubMed Web of Science ®Google Scholar
• Glantz MJ , ColeBF, RechtLet al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J. Clin. Oncol. 16(4), 1561–1567 (1998).
   PubMed Web of Science ®Google Scholar
• Cocconi G , LotticiR, BisagniGet al. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Invest.8(3–4), 327–334 (1990).
   PubMed Web of Science ®Google Scholar
• Sung C , BlaneySM, ColeDE, BalisFM, DedrickRL. A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Res.54(19), 5118–5122 (1994).
   PubMed Web of Science ®Google Scholar
• Baker SD , HeidemanRL, CromWR, KutteschJF, GajjarA, StewartCF. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother. Pharmacol.37(3), 195–202 (1996).
   PubMed Web of Science ®Google Scholar
• Oberhoff C , KiebackDG, WürstleinRet al. Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Onkologie24(3), 256–260 (2001).
   PubMedGoogle Scholar
• Kocher M , EichHT, SemrauR, GünerSA, MüllerRP. Phase I/II trial of simultaneous whole-brain irradiation and dose-escalating topotecan for brain metastases. Strahlenther. Onkol.181(1), 20–25 (2005).
   PubMed Web of Science ®Google Scholar
• Stupp R , MasonWP, van den BentMJet al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352(10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Abrey LE , OlsonJD, RaizerJJet al. A Phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J. Neurooncol.53(3), 259–265 (2001).
   PubMed Web of Science ®Google Scholar
• Christodoulou C , BafaloukosD, LinardouHet al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J. Neurooncol.71(1), 61–65 (2005).
   PubMed Web of Science ®Google Scholar
• Ekenel M , HormigoAM, PeakS, DeangelisLM, AbreyLE. Capecitabine therapy of central nervous system metastases from breast cancer. J. Neurooncol.85(2), 223–227 (2007).
   PubMed Web of Science ®Google Scholar
• Chargari C , KirovaYM, DierasVet al. Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients. J. Neurooncol.93(3), 379–384 (2009).
   PubMed Web of Science ®Google Scholar
• Lin NU , DierasV, PaulDet al. Multicenter Phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin. Cancer Res.15(4), 1452–1459 (2009).
   PubMed Web of Science ®Google Scholar
• Bachelot T , RomieuG, CamponeMet al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group Phase II study. Lancet Oncol.14(1), 64–71 (2013).
   PubMed Web of Science ®Google Scholar
• Capri G , ChangJ, ChenSCet al. An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann. Oncol.21(3), 474–480 (2010).
   PubMed Web of Science ®Google Scholar
• Harbeck N , HuangCS, HurvitzSet al. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, Phase III trial. Lancet Oncol.17(3), 357–366 (2016).
   PubMed Web of Science ®Google Scholar
• Cortes J , DierasV, RoJet al. Afatinib alone or afatinib plus vinorelbine versus investigator’s choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, Phase II trial. Lancet Oncol. 16(16), 1700–1710 (2015).
   PubMed Web of Science ®Google Scholar
• Freedman RA , GelmanRS, WefelJSet al. Translational Breast Cancer Research Consortium (TBCRC) 022: a Phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J. Clin. Oncol.34(9), 945–952 (2016).
   PubMed Web of Science ®Google Scholar
• Cortes J , O’ShaughnessyJ, LoeschDet al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a Phase III open-label randomised study. Lancet377(9769), 914–923 (2011).
   PubMed Web of Science ®Google Scholar
• Stemmler HJ , SchmittM, WillemsA, BernhardH, HarbeckN, HeinemannV. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier. Anticancer Drugs18(1), 23–28 (2007).
   PubMed Web of Science ®Google Scholar
• Park YH , ParkMJ, JiSHet al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br. J. Cancer100(6), 894–900 (2009).
   PubMed Web of Science ®Google Scholar
• Bartsch R , BerghoffA, PluschnigUet al. Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. Br. J. Cancer106(1), 25–31 (2012).
   PubMed Web of Science ®Google Scholar
• Bartsch R , RottenfusserA, WenzelCet al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J. Neurooncol.85(3), 311–317 (2007).
   PubMed Web of Science ®Google Scholar
• Yau T , SwantonC, ChuaSet al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol.45(2), 196–201 (2006).
   PubMed Web of Science ®Google Scholar
• Bendell JC , DomchekSM, BursteinHJet al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer97(12), 2972–2977 (2003).
   PubMed Web of Science ®Google Scholar
• Lin NU , CareyLA, LiuMCet al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol.26(12), 1993–1999 (2008).
   PubMed Web of Science ®Google Scholar
• Lin NU , FreedmanRA, RamakrishnaNet al. A Phase I study of lapatinib with whole brain radiotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Res. Treat.142(2), 405–414 (2013).
   PubMed Web of Science ®Google Scholar
• Kaplan MA , IsikdoganA, KocaDet al. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology. Breast Cancer21(6), 677–683 (2014).
   PubMed Web of Science ®Google Scholar
• Lin NU , EiermanW, GreilRet al. Randomized Phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J. Neurooncol.105(3), 613–620 (2011).
   PubMed Web of Science ®Google Scholar
• Martin M , BonneterreJ, GeyerCEJret al. A Phase II randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur. J. Cancer49(18), 3763–3772 (2013).
   PubMed Web of Science ®Google Scholar
• Saura C , Garcia-SaenzJA, XuBet al. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol.32(32), 3626–3633 (2014).
   PubMed Web of Science ®Google Scholar
• Morabito A , LongoR, GattusoDet al. Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer. Oncol. Rep.16(2), 393–398 (2006).
   PubMed Web of Science ®Google Scholar
• Mutlu H , BuyukcelikA. The combination of weekly trastuzumab plus vinorelbine may be preferable regimen in HER-2 positive breast cancer patients with brain metastasis. J. Oncol. Pharm. Pract.21(4), 310–312 (2015).
   PubMed Web of Science ®Google Scholar
• Iwamoto FM , OmuroAM, RaizerJJet al. A Phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. J. Neurooncol.87(1), 85–90 (2008).
   PubMed Web of Science ®Google Scholar
• Byun KD , AhnSG, BaikHJet al. Eribulin mesylate combined with local treatment for brain metastasis from breast cancer: two case reports. J. Breast Cancer19(2), 214–217 (2016).
   PubMed Web of Science ®Google Scholar
• Adams S , GrayRJ, DemariaSet al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two Phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J. Clin. Oncol.32(27), 2959–2966 (2014).
   PubMed Web of Science ®Google Scholar
• Ali HR , ProvenzanoE, DawsonSJet al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann. Oncol.25(8), 1536–1543 (2014).
   PubMed Web of Science ®Google Scholar
• Loi S , MichielsS, SalgadoRet al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann. Oncol.25(8), 1544–1550 (2014).
   PubMed Web of Science ®Google Scholar
• Mittendorf EA , CliftonGT, HolmesJPet al. Final report of the Phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann. Oncol.25(9), 1735–1742 (2014).
   PubMed Web of Science ®Google Scholar
• Dirix L , TakacsI, NikolinakosPet al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a Phase Ib JAVELIN solid tumor trial. Presented at: 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium. TX, USA, December 8–12 2015 ( Abstract S1-04).
   Google Scholar
• Rugo H , DelordJ-P, ImS-Aet al. Abstract S5–07: preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1-positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028. Cancer Res.76(Suppl. 4), S5–S7 (2016).
   Google Scholar
• Goldberg SB , GettingerSN, MahajanAet al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, Phase II trial. Lancet Oncol.17(7), 976–983 (2016).
   PubMed Web of Science ®Google Scholar
• Margolin K , ErnstoffMS, HamidOet al. Ipilimumab in patients with melanoma and brain metastases: an open-label, Phase II trial. Lancet Oncol.13(5), 459–465 (2012).
   PubMed Web of Science ®Google Scholar
• Di Giacomo AM , AsciertoPA, PillaLet al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm Phase II trial. Lancet Oncol.13(9), 879–886 (2012).
   PubMed Web of Science ®Google Scholar
• Di Giacomo AM , AsciertoPA, QueiroloPet al. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 Phase II study. Ann. Oncol.26(4), 798–803 (2015).
   PubMed Web of Science ®Google Scholar
• Barok M , IsolaJ, Palyi-KrekkZet al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol. Cancer Ther.6(7), 2065–2072 (2007).
   PubMed Web of Science ®Google Scholar
• Clynes R , KnutsonKL, BallmanKVet al. Combination trastuzumab and chemotherapy to induce immunity to multiple tumor antigens in patients with HER2-positive metastatic breast cancer: NCCTG (Alliance) studies N0337 and N98–32–52. J. Clin. Oncol.31(Suppl. 15), 521 (2013).
   Google Scholar
• Vonderheide RH , LorussoPM, KhalilMet al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin. Cancer Res.16(13), 3485–3494 (2010).
   PubMed Web of Science ®Google Scholar
• Ribas A . Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). Oncologist13(Suppl. 4), 10–15 (2008).
   PubMedGoogle Scholar
• Ribas A , CamachoLH, Lopez-BeresteinGet al. Antitumor activity in melanoma and anti-self responses in a Phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J. Clin. Oncol.23(35), 8968–8977 (2005).
   PubMed Web of Science ®Google Scholar
• Camacho LH , AntoniaS, SosmanJet al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J. Clin. Oncol.27(7), 1075–1081 (2009).
   PubMed Web of Science ®Google Scholar
• Tarhini AA , KirkwoodJM. Tremelimumab (CP-675, 206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers. Expert Opin. Biol. Ther.8(10), 1583–1593 (2008).
   PubMed Web of Science ®Google Scholar
• Mittendorf EA , PeoplesGE. Injecting hope – a review of breast cancer vaccines. Oncology30(5), 475–481, 485 (2016).
   PubMed Web of Science ®Google Scholar
• Pusztai L , KarnT, SafonovA, Abu-KhalafMM, BianchiniG. New strategies in breast cancer: immunotherapy. Clin. Cancer Res.22(9), 2105–2110 (2016).
   PubMed Web of Science ®Google Scholar
• Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer12(4), 252–264 (2012).
   PubMed Web of Science ®Google Scholar
• Keir ME , ButteMJ, FreemanGJ, SharpeAH. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol.26, 677–704 (2008).
   PubMed Web of Science ®Google Scholar
• Emens LA , BraitehFS, CassierPet al. Abstract 2859: inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC). Cancer Res.75(Suppl. 15), 2859 (2015).
   Google Scholar
• Adams S , DiamondJ, HamiltonEet al. Abstract P2–11–06: safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer. Cancer Res.76(Suppl. 4), P2–11–06 (2016).
   Google Scholar
• Nanda R , ChowLQ, DeesECet al. Abstract S1–09: a Phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. Cancer Res.75(Suppl. 9), S1–S9 (2015).
   Google Scholar
• Queirolo P , SpagnoloF, AsciertoPAet al. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J. Neurooncol.118(1), 109–116 (2014).
   PubMed Web of Science ®Google Scholar
• Knisely JP , YuJB, FlaniganJ, SznolM, KlugerHM, ChiangVL. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J. Neurosurgery117(2), 227–233 (2012).
   PubMed Web of Science ®Google Scholar
• Ongerboer de Visser BW , SomersR, NooyenWH, van HeerdeP, HartAA, McVieJG. Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology33(12), 1565–1572 (1983).
   PubMed Web of Science ®Google Scholar
• Glantz MJ , JaeckleKA, ChamberlainMCet al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res.5(11), 3394–3402 (1999).
   PubMed Web of Science ®Google Scholar
• Zagouri F , SergentanisTN, BartschRet al. Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. Breast Cancer Res. Treat.139(1), 13–22 (2013).
   PubMed Web of Science ®Google Scholar
• Jaeckle KA , PhuphanichS, BentMJet al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br. J. Cancer84(2), 157–163 (2001).
   PubMed Web of Science ®Google Scholar
• Lu NT , RaizerJ, GaborEPet al. Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient. J. Immunother. Cancer3, 41 (2015).
   PubMed Web of Science ®Google Scholar
• Park WY , KimHJ, KimKet al. Intrathecal trastuzumab treatment in patients with breast cancer and leptomeningeal carcinomatosis. Cancer Res. Treat.48(2), 843–847 (2016).
   PubMed Web of Science ®Google Scholar